Industry Liaison Forum

Case study 1: Exploring long-acting solutions for mothers and newborns

In 2022, our roundtable discussions on long-acting technologies had a wide impact; over 5,100 participants accessed roundtable resources, and they led to two articles in the JIAS supplement, “Advancing LAED HIV prevention and treatment regimens”. As these technologies advance, the group identified a new challenge: meeting the specific needs of pregnant and breastfeeding people and newborns, particularly in resource-limited settings. The Forum’s session at IAS 2023, “Advancing HIV care for mothers and newborns through long-acting solutions”, addressed obstacles in developing and implementing long-acting HIV prevention and treatment options for mothers and newborns and shared experiences and best practices. The session drew 200 participants, generating remarkable engagement: 15,957 impressions and 406 interactions on social media.

Case study 3: WHO Prequalification of In Vitro Diagnostics

In 2018, Forum industry partners published a perspective on World Health Organization (WHO) Prequalification of In Vitro Diagnostics in Clinical Infectious Diseases. In 2022, the Forum coordinated a roundtable discussion with representatives of regulatory and normative agencies, as well as the diagnostics and pharmaceutical industry, to introduce the newly published WHO collaborative procedure. This is a tool for national regulatory authorities that wish to enhance their pre-marketing and post-registration evaluation and registration of in vitro diagnostics. To access the roundtable materials, click here.